Products
Latest News
FAQ
|
Search
Search
Filters
Clear All
Study Phase
Early Phase 1
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase 4
Not Applicable
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Completed
Suspended
Terminated
Withdrawn
Study Type
Interventional
Observational
Expanded Access
Others
Eligibility Sex
All
Female
Male
Healthy Volunteers
All
Include
Exclude
Found
1
clinical trials
|
View Analysis
Sort by:
Newest First
Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)
Phase 2
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Placebo
Drug: NBI-1065845
Subscribe
First Posted Date
2022-01-24
Last Posted Date
2024-03-25
Lead Sponsor
Neurocrine Biosciences
Target Recruit Count
183
Registration Number
NCT05203341
Locations
🇸🇪
Neurocrine Clinical Site, Stockholm, Sweden
Subscribe
Prev
1
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy